The role of the renin angiotensin system in chronic renal disease

Bibliography

• THE NATIONAL INSTITUTES OF HEALTH: USRDS Annual Data Report 1994. NIDDK, Bethesda, MD (1994).
   Google Scholar
• National High Blood Pressure Education Program working group report on hypertension and chronic renal failure. Arch. Intern. Med. (1991) 151:1280–1287.
   Google Scholar
• ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hy-pertension in the rat. J. Clin. Invest. (1986) 77:1993–2000.
   PubMed Web of Science ®Google Scholar
• MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Re-versing glomerular hypertension stabilizes established glomerular injury. Kidney Int. (1987) 31:752–759.
   PubMed Web of Science ®Google Scholar
• FOGO A, YOSHIDA Y, GLICK AD, HOMMA H, ICHIKAWA I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J. Clin. Invest. (1988) 82:322–330.
   PubMed Web of Science ®Google Scholar
• LAFAYETTE RA, MAYER G, PARK SG, MEYER TW: Angio-tensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. (1992) 90:766–771.
   PubMed Web of Science ®Google Scholar
• KAMPER A-L, STRANDGAARD S, LEYSSAC PP: Effect ofenalapril on the progression of chronic renal failure. A randomized controlled trial. Am. J. Hypertens. (1992) 5:423–430.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, RHODE RD: The effectof angiotensin -converting- enzyme inhibition on dia-betic nephropathy. New Engl. J.Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• BRENNER, BM: Nephron adaptation to renal injury orablation. Am. J. Physiol. (1985) 249:F324–337.
   PubMed Web of Science ®Google Scholar
• HEYMANN W, HACKEL DB, HARWOOD S, WILSON SGF,HUNTER JLP: Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. (1959) 100:660–664.
   PubMed Web of Science ®Google Scholar
• GABBAI FB, GUSHWA LC, WILSON CB, BLANTZ RC: Anevaluation of the development of experimental mem-branous nephropathy. Kidney Int. (1987) 31:1267–278.
   PubMed Web of Science ®Google Scholar
• DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am. J. Pathol. (1986) 122:481–487.
   PubMed Web of Science ®Google Scholar
• HOSTETTER TH: Pathogenesis of diabetic nephropathy.In: The Progressive Nature of Renal Disease. Mitch WE, Bren-ner BM, Stein JH (Eds.), Churchill Livingstone, New York (1986) :149–166.
   Google Scholar
• MAUER SM, STEFFES MW, AZAR S, SANBERG SK, BROWNDM: The effects of Glodblatt hypertension on develop-ment of the glomerular lesions of diabetes mellitus in the rat. Diabetes (1978) 27:738–744.
   PubMed Web of Science ®Google Scholar
• HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHA-LAM MA, BRENNER BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal abla-tion. Am. J. Physic)]. (1981) 241:F85–93.
   PubMed Web of Science ®Google Scholar
• NATH KA, KREN SM, HOSTETTER TH: Dietary protein re-striction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction. J. Clin. Invest. (1986) 78:1199–1205.
   Google Scholar
• STEFFES MW, BROWN DM, MAUER SM: Diabetic glomeru-lopathy following unilateral nephrectomy in the rat. Diabetes (1978) 27:35–41.
   PubMed Web of Science ®Google Scholar
• FOGO A, ICHIKAWAI: Evidence for the central role of glomerular growth promoters in the development of sclerosis. Sem. Nephrol (1989) 9:329–342.
   PubMed Web of Science ®Google Scholar
• RAIJ L, KEANE WF: Glomerular mesangium: its function and relationship to angiotensin II. Am. J. Med. (1985) 79\(Suppl. 30:24–30.
   Google Scholar
• ANDERSON S: Pharmacological intervention for pro-gressive renal failure in experimental models. In: Pre-vention of Progressive Renal Failure. El Nahas AM, Mallick NP, Anderson S (Eds.), Oxford University Press, Oxford (1993):171–209.
   Google Scholar
• ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. (1985) 76:612–619.
   PubMed Web of Science ®Google Scholar
• BRUNNER FP THIEL G, HERMLE M, BOCK HA, AND MI-HATSCH M: Long-term enalapril and verapamil in rats with reduced, renal mass. KidneyInt. (1989) 36:969–977.
   PubMed Web of Science ®Google Scholar
• YOSHIDA Y, KAWAMURA T, IKOMA M, FOGO A, AND ICHIKAWA I: Effects of antihypertensive drugs on glom-erular morphology. Kidney Int. (1989) 36:626–635.
   PubMed Web of Science ®Google Scholar
• TOLINS JP, RAU L: Comparison of converting enzyme in-hibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension (1990) 16:452–461.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, BERTANI T: Is glomerulosclerosis a conse-quence of altered glomerular permeability to macro-molecules? Kidney Intern. (1990) 38:384–394.
   Google Scholar
• DIAMOND JR, ANDERSON S: Irreversible tubulointersti-tial damage associated with chronic aminonucleoside nephrosis: amelioration by angiotensin 1 converting enzyme inhibition. Am. J. Pathol (1990) 137:1323–1332.
   PubMed Web of Science ®Google Scholar
• REMUZZI A, PUNTORIERI S, BATTAGLIA C, BERTANI T, RE-MUZZI G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J. Clin. Invest. (1990) 85:541–549.
   PubMed Web of Science ®Google Scholar
• SCHOLEY JW, MEYER TW: Control of glomerular hyper-tension by insulin administration in diabetic rats. J. Clin. Invest. (1989) 83:1384–1389.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK, MEGGS LG, WILLIAMS GH et al.: So-dium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. (1987) 20:240–245.
   Google Scholar
• NAVIS GJ, DE JONG PE, DONKER AJM et al.: Diuretic ef-fects of ACE-inhibition: comparison of low and liberal sodium diet in hypertensive patients. J. Cardiovasc. Pharmacol. (1987) 9:743–748.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, LAHERA V, ALCAZAR JM et al.. Randomly allocated study of the effects of standard therapy vs. ACE inhibition on microalbuminuria in essential hyperten-sion J. Hypertens. (1994) 12 (Suppl 4):S59–S63
   Google Scholar
• MADHAVEN S, STOCKWELL D, COHEN H et al.: Renalfunction during antihypertensive treatment. Lancet (1995) 345:749–751.
   PubMed Web of Science ®Google Scholar
• HIMMELMAN, HANSSON L, HANSSON B-G et aL: ACE-inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press. (1995) 4:85–90.
   PubMedGoogle Scholar
• HIMMELMAN, HANSSON L, HANSSON B-G eta].: Supior re-nal preservation with an ACE-inhibitor in essential hy-pertension: a transient effect? Proceedings of the 7th European Meeting of Hypertension. Milan, IT (June 1995).
   Google Scholar
• BRAVO EL, TARAZI RC: Efficacy of an orally active con-verting enzyme inhibitor (SQ 14,225) in the treatment of renovascular hypertension (RVH) in man. Kidney Int. (1977) 12:497–450.
   Web of Science ®Google Scholar
• KON V, FOGO A, ICHIKAWA I: Bradykinin causes selec-tive efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Intern. (1993) 44:545–550.
   PubMed Web of Science ®Google Scholar
• PARVING H-H, HOMMEL E, SMIDT UM: Protection of kid-ney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. Br. Med. J. (1988) 297:1086–1091.
   PubMed Web of Science ®Google Scholar
• RAVID M, SAVIN H, JUTRIN Y et al.: Long term stabilizingeffect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann. Intern. Med. (1993) 118:577–581.
   PubMed Web of Science ®Google Scholar
• BJOREK S, NYBERG G, MULEE H et al.: Beneficial effects ofangiotensin converting enzyme inhibition of renal function in patients with diabetic nephropathy. Br. Med. J. (1986) 293:467–470.
   PubMedGoogle Scholar
• BJOREK S, MULEE H, JOHNSEN SA et al.: Renal protectiveeffects of enalapril in diabetic nephropathy. Br. Med. J. (1992) 304:339–343.
   PubMed Web of Science ®Google Scholar
• PARVING HH, ANDERSON AR, SMIDT UM et al.: Effect ofantihypertensive treatment on kidney function in dia-betic nephropathy. Br Med. J. (1987) 294:1443–1447.
   PubMed Web of Science ®Google Scholar
• KASISKE B, KALIL RSN, MA JZ et al.: Effect of antihyper-tensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann. Intern. Med. (1993) 118:129–138.
   PubMed Web of Science ®Google Scholar
• REMUZZI A, PERICO N, AMUCHASTEGUI CS et al.: Short-and long-term effect of angiotensin II receptor block-ade in rats with experimental diabetes. J. Am. Soc. Neph-rol. (1993) 4:40–49.
   PubMed Web of Science ®Google Scholar
• VIBERTI GC, MOGENSEN CE, GROOP LC et al.: Effect ofcaptopril on progression to clinical proteinuria in pa-tients with insulin dependent diabetes mellitus and mi-croalbuminuria. JAMA (1994) 271:275–279.
   PubMed Web of Science ®Google Scholar
• MATHIESEN ER, HOMMEL E, GIESE J et al.: Efficacy of cap-topril in postponing nephropathy in normotensive in-sulin dependent diabetic patients with microalbuminuria. Br. Med. J. (1991) 303:81–87.
   PubMed Web of Science ®Google Scholar
• RAVID M, LANG R, RACHMANI R et al. Long-term renoprotective effect of angiotensin-converting enzyme in-hibition in non-insulin dependent diabetes mellitus: a 7-year follow-up. Arch. Intern. Med. (1996) 156:286–289.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, WIEGMANN TB, CANAN A et al: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney mt. (1994) 150\(Suppl. 145):S155–S155.
   Google Scholar